Contribution of Cryptic Epitopes in Designing a Group A Streptococcal Vaccine

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2018 Jun 7

PMID 29873591

Citations 9

Authors

Victoria Ozberk

Manisha Pandey

Michael F Good

Affiliations

Soon will be listed here.

Abstract

A successful vaccine needs to target multiple strains of an organism. Streptococcus pyogenes is an organism that utilizes antigenic strain variation as a successful defence mechanism to circumvent the host immune response. Despite numerous efforts, there is currently no vaccine available for this organism. Here we review and discuss the significant obstacles to vaccine development, with a focus on how cryptic epitopes may provide a strategy to circumvent the obstacles of antigenic variation.

Citing Articles

Streptococcus pyogenes pharyngitis elicits diverse antibody responses to key vaccine antigens influenced by the imprint of past infections.

Osowicki J, Frost H, Azzopardi K, Whitcombe A, McGregor R, Carlton L Nat Commun. 2024; 15(1):10506.

PMID: 39627204 PMC: 11614873. DOI: 10.1038/s41467-024-54665-5.

A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function.

Bahnan W, Happonen L, Khakzad H, Kumra Ahnlide V, de Neergaard T, Wrighton S EMBO Mol Med. 2022; 15(2):e16208.

PMID: 36507602 PMC: 9906385. DOI: 10.15252/emmm.202216208.

Immunogenicity and Protective Capacity of a Virus-like Particle Vaccine against Type 3 Secretion System Tip Protein, CT584.

Webster E, Seiger K, Core S, Collar A, Knapp-Broas H, Graham J Vaccines (Basel). 2022; 10(1).

PMID: 35062772 PMC: 8779370. DOI: 10.3390/vaccines10010111.

Structural determination of Streptococcus pyogenes M1 protein interactions with human immunoglobulin G using integrative structural biology.

Khakzad H, Happonen L, Karami Y, Chowdhury S, Erturk Bergdahl G, Nilges M PLoS Comput Biol. 2021; 17(1):e1008169.

PMID: 33411763 PMC: 7817036. DOI: 10.1371/journal.pcbi.1008169.

Antibodies to Variable Domain 4 Linear Epitopes of the Major Outer Membrane Protein Are Not Associated with Chlamydia Resolution or Reinfection in Women.

Collar A, Linville A, Core S, Wheeler C, Geisler W, Peabody D mSphere. 2020; 5(5).

PMID: 32968007 PMC: 7568647. DOI: 10.1128/mSphere.00654-20.

References

Guzman C, Talay S, Molinari G, Medina E, Chhatwal G . Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis. 1999; 179(4):901-6. DOI: 10.1086/314655. View

GOODFELLOW A, Hibble M, Talay S, Kreikemeyer B, Currie B, Sriprakash K . Distribution and antigenicity of fibronectin binding proteins (SfbI and SfbII) of Streptococcus pyogenes clinical isolates from the northern territory, Australia. J Clin Microbiol. 2000; 38(1):389-92. PMC: 88729. DOI: 10.1128/JCM.38.1.389-392.2000. View

Brandt E, Sriprakash K, Hobb R, Hayman W, Zeng W, Batzloff M . New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med. 2000; 6(4):455-9. DOI: 10.1038/74719. View

Wolfe R . Incidence of acute rheumatic fever: a persistent dilemma. Pediatrics. 2000; 105(6):1375. View

Cunningham M . Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000; 13(3):470-511. PMC: 88944. DOI: 10.1128/CMR.13.3.470. View

McCormick J, Tripp T, Olmsted S, Matsuka Y, Gahr P, Ohlendorf D . Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol. 2000; 165(4):2306-12. DOI: 10.4049/jimmunol.165.4.2306. View

Roggiani M, Stoehr J, Olmsted S, Matsuka Y, Pillai S, Ohlendorf D . Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun. 2000; 68(9):5011-7. PMC: 101724. DOI: 10.1128/IAI.68.9.5011-5017.2000. View

Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi K, Totsuka K . Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun. 2001; 69(2):924-30. PMC: 97971. DOI: 10.1128/IAI.69.2.924-930.2001. View

Quinn A, Kosanke S, Fischetti V, Factor S, Cunningham M . Induction of autoimmune valvular heart disease by recombinant streptococcal m protein. Infect Immun. 2001; 69(6):4072-8. PMC: 98471. DOI: 10.1128/IAI.69.6.4072-4078.2001. View

10.

Rathore D, Sacci J, De La Vega P, McCutchan T . Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J Biol Chem. 2001; 277(9):7092-8. DOI: 10.1074/jbc.M106862200. View

11.

Galvin J, Hemric M, Kosanke S, Factor S, Quinn A, Cunningham M . Induction of myocarditis and valvulitis in lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol. 2002; 160(1):297-306. PMC: 1867128. DOI: 10.1016/S0002-9440(10)64373-8. View

12.

Pittman P, Pifat D, Coonan K, Gibbs P, Little S, Pace-Templeton J . Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine. 2002; 20(9-10):1412-20. DOI: 10.1016/s0264-410x(01)00462-5. View

13.

Hu M, Walls M, Stroop S, Reddish M, Beall B, Dale J . Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun. 2002; 70(4):2171-7. PMC: 127884. DOI: 10.1128/IAI.70.4.2171-2177.2002. View

14.

Cheng Q, Stafslien D, Purushothaman S, Cleary P . The group B streptococcal C5a peptidase is both a specific protease and an invasin. Infect Immun. 2002; 70(5):2408-13. PMC: 127948. DOI: 10.1128/IAI.70.5.2408-2413.2002. View

15.

Olive C, Batzloff M, Horvath A, Wong A, Clair T, Yarwood P . A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun. 2002; 70(5):2734-8. PMC: 127950. DOI: 10.1128/IAI.70.5.2734-2738.2002. View

16.

Olive C, Clair T, Yarwood P, Good M . Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine. 2002; 20(21-22):2816-25. DOI: 10.1016/s0264-410x(02)00205-0. View

17.

Reid S, Green N, Sylva G, Voyich J, Stenseth E, DeLeo F . Postgenomic analysis of four novel antigens of group a streptococcus: growth phase-dependent gene transcription and human serologic response. J Bacteriol. 2002; 184(22):6316-24. PMC: 151937. DOI: 10.1128/JB.184.22.6316-6324.2002. View

18.

Batzloff M, Hayman W, Davies M, Zeng M, Pruksakorn S, Brandt E . Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis. 2003; 187(10):1598-608. DOI: 10.1086/374800. View

19.

Kirvan C, Swedo S, Heuser J, Cunningham M . Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003; 9(7):914-20. DOI: 10.1038/nm892. View

20.

Courtney H, Hasty D, Dale J . Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun. 2003; 71(9):5097-103. PMC: 187301. DOI: 10.1128/IAI.71.9.5097-5103.2003. View